Regeneron Provides Update On Planned Chief Financial Officer Transition; Robert E. Landry, Will Retire In February 2024. Christopher Fenimore, Will Succeed Mr. Landry As CFO Upon His Retirement
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that its CFO, Robert E. Landry, will retire in February 2024. He will be succeeded by Christopher Fenimore, the current Senior Vice President, Head of Accounting and Controller at Regeneron. Fenimore has been with the company since 2003 and holds global responsibility for U.S. SEC reporting, accounting operations, and is co-leading the company's international expansion strategy.
September 08, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron's CFO, Robert E. Landry, is set to retire in 2024 and will be succeeded by Christopher Fenimore. This planned transition may bring continuity and collaboration across the organization.
The planned CFO transition at Regeneron is a significant event, but it's not expected to cause any immediate disruption as it's a planned and smooth transition. Fenimore's experience and current role in the company suggest he is well-prepared for the CFO role, which could ensure continuity and collaboration across the organization.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100